Physician profile
Dhiren B Patel
NPI 1528078466
$20,725.26
in general payments reported to CMS, 2019-2025
41 companies · $2,958 in 2025
The $2,958 reported for 2025 was more than what 94% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,499 · 2020: $1,295 · 2021: $2,086 · 2022: $1,612 · 2023: $3,143 · 2024: $4,132 · 2025: $2,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $13.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,219.65 |
| Education | $13.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,626.81 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $2,545.26 | 2019-2025 | Rexulti, Abilify Mycite |
| Lundbeck LLC | $1,337.13 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,301.87 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,164.00 | 2021-2025 | Caplyta |
| Tris Pharma INC | $1,055.73 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Abbvie INC. | $1,033.72 | 2021-2025 | |
| Indivior INC. | $833.25 | 2019-2025 | Sublocade |
| Corium, LLC | $725.57 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $586.63 | 2021-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $552.92 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $493.02 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $406.03 | 2019-2024 | Jornay Pm |
| Bausch Health US, LLC | $376.33 | 2021-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $368.33 | 2023-2025 | Auvelity |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $361.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $360.91 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $231.41 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $229.52 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Neos Therapeutics, Lp | $226.95 | 2019-2025 | Adzenys Xr-Odt |
| Eisai INC. | $221.72 | 2020-2022 | |
| Orexo US, INC. | $215.21 | 2019-2024 | Zubsolv |
| Idorsia Pharmaceuticals US INC | $213.03 | 2022-2024 | Quviviq |
| Shire North American Group INC | $179.84 | 2019 | |
| Braeburn INC. | $172.02 | 2023-2024 | Brixadi |
| Noven Therapeutics, LLC | $156.12 | 2023-2025 | Secuado, Xelstrym |
| Vanda Pharmaceuticals INC. | $102.34 | 2022-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $92.65 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $88.82 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $87.35 | 2019-2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $63.06 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $50.08 | 2024-2025 | Cobenfy |
| Merck Sharp & Dohme LLC | $43.91 | 2022-2023 | Belsomra |
| Pear Therapeutics (US), INC. | $39.85 | 2022 | |
| Owp Pharmaceuticals, INC. | $36.01 | 2023-2024 | Subvenite, Lamotrigine |
| Adlon Therapeutics L.P. | $34.71 | 2019-2020 | |
| Tempus Ai, INC | $33.84 | 2024 | |
| Arbor Pharmaceuticals, INC. | $28.51 | 2019 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Uswm, LLC | $14.50 | 2021 | |
| Amgen INC. | $14.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhiren Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.